Clinical features of patients newly diagnosed between 2005 and 2014
| Variable . | CLL (n = 479; 72%) . | SLL (n = 95; 14%) . | MBL (n = 86; 13%) . | All patients (N = 660) . |
|---|---|---|---|---|
| Ratio of males to females | 299:179 (1.6:1) | 57:38 (1.5:1) | 53:34 (1.6:1) | 409:251 (1.6:1) |
| Median age (range), y | 68 (37-99) | 68 (34-91) | 70 (45-93) | 68 (34-99) |
| CLL Rai stage | ||||
| 0 | 263 (55) | |||
| I/II | 167 (35) | |||
| III/IV | 48 (48) | |||
| Lymphocyte doubling time, mo | ||||
| <6 | 38 (8) | 3 (3) | 1 (1) | 42 (6) |
| 6-12 | 67 (14) | 10 (11) | 3 (3) | 80 (12) |
| >12 | 361 (76) | 82 (86) | 80 (92) | 523 (79) |
| Ratio of mutated IGHV to unmutated IGHV | 189/150 (1.3:1) | 25/24 (1:1) | 42/11 (3.8:1) | 256/185 (1.4:1) |
| Ratio of ZAP-70 positive/ZAP-70 negative | 122/275 (1:2.3) | 20/40 (1:2) | 14/54 (1:3.9) | 156/369 (1:2.4) |
| Ratio of CD38 positive/CD38 negative | 118/299 (1:2.5) | 37/34 (1.1:1) | 10/63 (1:6.3) | 165/396 (1:2.5) |
| Ratio of B2M high/B2M normal | 152/90 (1.7:1) | 37/29 (1.3:1) | 14/30 (1:2.1) | 203/149 (1.4:1) |
| Chemotherapy | ||||
| For CLL | 232 (48) | 55 (58) | 7 (8) | 294 (44) |
| For solid tumors | 6 (1) | 2 (1) | 1 (1) | 9 (1) |
| IgG replacement | 41 (9) | 4 (4) | 4 (5) | 49 (7) |
| Deaths | 144 (30) | 25 (26) | 11 (13) | 180 (27) |
| Mean CIRS | 5 | 5 | 4 | 5 |
| Variable . | CLL (n = 479; 72%) . | SLL (n = 95; 14%) . | MBL (n = 86; 13%) . | All patients (N = 660) . |
|---|---|---|---|---|
| Ratio of males to females | 299:179 (1.6:1) | 57:38 (1.5:1) | 53:34 (1.6:1) | 409:251 (1.6:1) |
| Median age (range), y | 68 (37-99) | 68 (34-91) | 70 (45-93) | 68 (34-99) |
| CLL Rai stage | ||||
| 0 | 263 (55) | |||
| I/II | 167 (35) | |||
| III/IV | 48 (48) | |||
| Lymphocyte doubling time, mo | ||||
| <6 | 38 (8) | 3 (3) | 1 (1) | 42 (6) |
| 6-12 | 67 (14) | 10 (11) | 3 (3) | 80 (12) |
| >12 | 361 (76) | 82 (86) | 80 (92) | 523 (79) |
| Ratio of mutated IGHV to unmutated IGHV | 189/150 (1.3:1) | 25/24 (1:1) | 42/11 (3.8:1) | 256/185 (1.4:1) |
| Ratio of ZAP-70 positive/ZAP-70 negative | 122/275 (1:2.3) | 20/40 (1:2) | 14/54 (1:3.9) | 156/369 (1:2.4) |
| Ratio of CD38 positive/CD38 negative | 118/299 (1:2.5) | 37/34 (1.1:1) | 10/63 (1:6.3) | 165/396 (1:2.5) |
| Ratio of B2M high/B2M normal | 152/90 (1.7:1) | 37/29 (1.3:1) | 14/30 (1:2.1) | 203/149 (1.4:1) |
| Chemotherapy | ||||
| For CLL | 232 (48) | 55 (58) | 7 (8) | 294 (44) |
| For solid tumors | 6 (1) | 2 (1) | 1 (1) | 9 (1) |
| IgG replacement | 41 (9) | 4 (4) | 4 (5) | 49 (7) |
| Deaths | 144 (30) | 25 (26) | 11 (13) | 180 (27) |
| Mean CIRS | 5 | 5 | 4 | 5 |
All data are n (%) unless otherwise indicated. All values are rounded up to the nearest whole number.